natgillin/translations-raw huggingface dataset:
Ah1 is a heteroaryl-aryl radical or an aryl-heteroaryl radical made up of a heteroaryl group selected from a group consisting of monocyclic 5- or 6-membered heteroaryl radicals comprising one or two heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, and an aryl group selected from a group consisting of phenyl and naphthyl, whereby said heteroaryl and aryl groups are linked together via a single bond, 
Ahl je heteroaril-arilni radikal ili aril-heteroarilni radikal, kojeg čine heteroarilna skupina, koju se bira iz skupine koju čine monociklički 5- ili 6-eročlani heteroarilni radikali, koji sadrže jedan ili dva heteroatoma, od kojih se svakog bira iz skupine koju čine dušik, kisik i sumpor, i arilna skupina, koju se bira iz skupine koju čine fenil i naftil, gdje su navedene heteroarilne i arilne skupine vezane zajedno jednostrukom vezom,
Soluble (S1) fraction (20h induction at 22°C) conserved at -20°C. Thawed and centrifuged at 20.000g/30 min: S2 and P2 (resuspended in 1/10 vol.) 
S1: topiva frakcija (3 sata indukcije na 30 %C), čuvana na -20 "€, odmrznuta i centrifugirana 30 minuta na 20.000 g. S2 P2 (resuspendiran u 1/10 volumena)
The method according to claim 4, wherein, when the wet adhesive composition is obtained from the composition of (b), the plasticizer is contained in amounts ranging from 15% to 20% by weight of the total weight of said adhesive wet composition. 
Uporaba u skladu s patentnim zahtjevom 2, pri čemu, kada su navedeni adhezivni sastavi dobiveni od mokrog sastava tipa (b), omi sadrže količine plastifikatora u rasponu od 15-20% prema težini u odnosu na ukupnu težinu mokrih sastava.
“Heteroaryl” means a monocyclic or multicyclic aromatic ring system of about 5 to about 14 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the atoms in the ring system is/are atoms other than carbon, for example nitrogen, oxygen or sulfur. 
"heteroaril" znači monociklički ili policiklički aromatski prstenasti sustav s 5 do 14 atoma u prstenu, gdje jedan ili više atoma u prstenastom sustavu je/su atomi koji nisu ugljik.
The surface under the top has two sections, the one has containers where liquids are placed and in the other there is an opening through which the apiculturist can watch, feed and do whatever work needs immediate contact with the bees. 
Površina ispod gornjeg dijela ima dva dijela, jedan ima spremnike u koje se stavljaju tekućine, a u drugom je otvor kroz koji promatramo i hranimo pčele i radimo sve što je potrebno u poslu koji zahtjeva neposredan dodir sa pčelama.
The aqueous formulation of claim 2 comprising 0.1 µg to 10 µg lixisenatide per U insulin glargine, preferably 0.2 to 1 µg lixisenatide per U insulin glargine, more preferably 0.25 µg to 0.7 µg lixisenatide per U insulin glargine. 
Vodena formulacija prema zahtjevu 1 ili 2 naznačena time da sadrži 0.1 ug do 10 ug liksisenatida po jedinici inzulin glargina, poželjno 0.2 do 1 ug liksisenatida po jedinici inzulin glargina, i more poželjno 0.25 ug do 0.7 ug liksisenatida po jedinici inzulin glargina.
A compound in accordance with claim 1 selected from the following table: or a pharmaceutically acceptable salt or solvate thereof. 
LALA MALLA NAME AAA LEKA LLLLAALA LE LLLLLLILNA KALLE LLILLLIMARA LL ALLLLLLAA LALA ALLA: ili njegova farmaceutski prihvatljiva sol ili solvat.
P9700589 suggests that in case of venlafaxine hydrochloride having a solubility higher than 500 mg/ml pelletization can be performed only by the application of microcrystalline cellulose combined with hydroxypropyl-methyl cellulose. 
P9700589 sugerira da se u slučaju venlafaksin hidroklorida čija je topljivost veća od 500 mg/ml granuliranje može izvršiti samo primjenom mikrokristalne celuloze koja je kombinirana s hidroksipropil-metil celulozom.
A well apparatus as claimed in claim 6, wherein sensors and/or receivers (360) are provided in at least one casing annulus defined between two of the casing strings (12a,12b,12c,12d). 
Bunarska aparatura, sukladno patentnom zahtjevu 10, naznačeno time, da su senzori i/ili prijemnici (360) je osigurani u najmanje jednom kućišnom anulusu definiranom između dvije kućišne žice (12a,12b,12c,12d).
System according to anyone of claims 10 to 16, wherein the concentrator (C) is adapted to perform the operation of determining on the basis of said status data whether sufficient consumption related data are stored at the remote meter (RM). 
Sustav prema bilo kojem od patentnih zahtjeva 10 do 16, pri čemu je sabirnik (C) prilagođen za provođenje operacija utvrđivanja na temelju navedenih trenutnih podataka je li dovoljan broj navedenih periodički izmjerenih i pohranjenih podataka vezanih uz potrošnju pohranjen na daljinskom brojaču (RM).
A treated RNA composition produced using the method of any of Claims 1-11 for use in the treatment of regenerative medicine, cell reprogramming, cell-based therapies, enzyme replacement therapies, cell, tissue and organ transplantation or repair, tissue or organ engineering, and/or immunotherapies. 
Obrađeni sastav ribonukleinske kiseline prema bilo kojem od zahtjeva 1-8, naznačen time, da se upotrebljava u liječenju regenerativnom medicinom, reprogramiranjem stanica, terapijom na stanici, nadomjesnom enzimskom terapijom, presađivanjem ili popravkom stanica, tkiva i organa, inženjeringom tkiva ili organa ili imunoterapijom.
Use according to any one of the preceding claims, characterized in that following the addition of said 2-((1-methylpropyl)amino)ethanol, the suspension conductivity does not change by more than 10 %, preferably does not change by more than 6 %, and more preferably does not change by more than 3 %. 
Uporaba u skladu s bilo kojim od prethodnih patentnih zahtjeva, karakterizirana na način da se nakon dodavanja navedenog 2-((1-metilpropil)amino)etanola, promjena vodljivosti otopine ne mijenja za više od 10 %, poželjno se ne mijenja za više od 6 %, poželjnije se ne mijenja za više od 3 %.
The compound according to claim 6, wherein R1 is: wherein the symbols have the following meanings: 
[image] gdje simboli imaju sljedeća značenja: je predstavljen formulom (II): [image]
20, 22, 24 or 29 are replaced by a mixture of primers comprising or consisting of the sequences of SEQ ID NOs. 14 and 15. 
28 za kvantifikaciju DNK sekvenci konjetine (Equus caballus), ili 1) = početnice sadržeći ili sastojeći se od sekvenci SEQ ID NOS.
Nevertheless, the low melting point of hydrogen succinate and hydrogen maleate salts made them less suitable for industrial application than monohydrochloride salt, due to a low melting point makes difficult the dry operations, also at moderate temperatures. 
Bez obzira na to, niska točka taljenja vodikovog sukcinata i vodikovih maleatnih soli činila ih je manje prikladnim za industrijsku primjenu nego monohidrokloridnu sol, s obzirom na nisku točku taljenja suhe operacije postaju teške, čak 1 na umjerenim temperaturama.
In another embodiment of the invention, the antibody-like binding proteins comprise two polypeptide chains that form two antigen binding sites capable of specifically binding one or more antigen targets, wherein a first polypeptide chain has a structure represented by the formula: 
Protutijelu sličan vezivni protein koji sadrži dva polipeptidna lanca koji tvore dva mjesta vezivanja antigena, pri čemu prvi polipeptidni lanac ima strukturu predstavljenu s formulom: Vrr-Li-VL2-L2-CL
The antagonist of claims 1-3, wherein the half-life extending moiety is conjugated to the peptide antagonist of Kv1.3 via a linker, optionally wherein the linker comprises the amino sequence of SEQ ID NOs: 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122 or 428. 
Antagonisti prema zahtjevima 1-3, naznačen time da je ostatak za produljenje polu-života konjugiran na peptidni antagonist Kvl.3 pomoću skupine za povezivanje, proizvoljno gdje skupina za povezivanje sadrži sekvencu aminokiselina SEQ ID NOs: 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122 ili 428.
The topical composition according to claim 7, wherein the pharmaceutically acceptable carrier is an aqueous gel comprising water, and a water-gelling amount of a pharmaceutically acceptable gelling agent selected from the group consisting of carbomers, glycerine polyacrylate, and mixtures thereof, the topical composition having a physiologically acceptable pH. 
Topička kompozicija za uporabu prema patentnom zahtjevu 4, naznačeno time da je farmaceutski prihvatljiv nosač vodeni gel koji sadrži vodu, a voda-gelirajući sadržaj farmaceutski prihvatljivog gelirajućeg sredstva izabranog iz grupe koja se sastoji od karbomera, glicerin poliakrilata, i njihovih smjesa, topička kompozicija ima fiziološki prihvatljiv pH.
The microcapsules according to claim 1, wherein the microcapsule contains the liver cells and the erythropoietin embedded in a biocompatible matrix. 
Postupak za kultiviranje stanice jetre u mediju za kultiviranje naznačen time da se sastoji od kultiviranja mikrokapsule prema bilo kojem zahtjevu od 1 do 13 u pogodnom mediju za kultiviranje.
The system of claim 40, wherein one or both of the nucleic acids of a) and b) are one or more vectors and wherein the nucleotide sequence encoding said Cas9 protein and/or the nucleotide sequence encoding said single molecule DNA-targeting RNA are operably linked to a control element operable in a desired cell type. 
Jedna ili više nukleinskih kiselina u skladu s patentnim zahtjevom 13 ili patentnim zahtjevom 14, naznačene time što je nukleotidni slijed koji kodira navedena RNA koja cilja na DNA operabilno spregnut s promotorom koji funkcionira u eukariotskoj stanici, i/ili je nukleotidni slijed koji kodira polipeptid Cas9 operabilno spregnut s promotorom koji funkcionira u eukariotskoj stanici.
The IL-2 was oxidized in order to obtain the intramolecular disulfide bond. 
IL-2 je oksidiran da bi se dobila intramolekularna disulfidna veza.
a device configured to gasify the LNG installed downstream of the second pump, to gasify the compressed LNG. The fuel gas supply system of a vessel according to claim 1, further comprising a fuel gas supply line connected from the LNG tank to the high-pressure gas injection engine of the vessel, wherein a boil-off gas reliquefaction apparatus includes a heat exchanger . The fuel gas supply system of a vessel according to claim 2 wherein the boil-off gas from an upper portion of the LNG tank is in thermal communication with LNG while passing through the heat exchanger and then is supplied to the LNG tank. 
Sustav dobave pogonskog plina za brod prema zahtjevu 4, naznačen time da dodatno sadrži: izmjenjivač topline (3) instaliran između jedne crpke i druge crpke u vodu za opskrbu pogonskim plinom; i vod za ukapljivanje isparenog plina koji prolazi kroz izmjenjivač topline iz gornjeg dijela spremnika LNG i spojen je između izmjenjivača topline i sredstava za uplinjavanje. Sustav dobave pogonskog plina za brod prema zahtjevu 3, naznačen time da dodatno sadrži: rekondenzator (103) instaliran nizvodno od jedne crpke u vodu za opskrbu pogonskim plinom; i vod za ukapljivanje isparenog plina spojen iz gornjeg dijela spremnika LNG, koji prolazi kroz rekondenzator, te prema spremniku LNG.
The method according to claim 1, wherein the flame retardant chemical composition comprises a preservative compound. The method according to claim 21, wherein the preservative compound is a source of benzoate ion. The method according to claim 21, wherein the preservative compound forms between 0.25% and 15% by weight of the flame retardant chemical composition. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da kemijsko sredstvo za usporavanje plamena sadržava pripravak za regulaciju pH, na primjer slabu organsku kiselinu. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da kemijsko sredstvo za usporavanje plamena sadržava konzervans, na primjer izvor benzoat iona.
a first layer wherein the first layer is a metformin extended release formulation comprising 50-87% metformin hydrochloride, 1-10% sodium carboxymethyl cellulose, 10-40% hydroxypropyl methylcellulose, 0.1-75% magnesium stearate, and 0-2% silicon dioxide or 0-1.5% colloidal silicon dioxide; 
Dvoslojna tableta prema bilo kojem od zahtjeva 1-3, naznačena time što (1) prvi sloj sadrži 69% metformin hidroklorida, 3.5% natrijeve karboksimetil celuloze, 27% hidroksipropil metilceluloze 2208, i 0.48% magnezijevog stearata; i (2) drugi sloj je 300 mg do 400 mg.
The method of claim 7, wherein the bacterium is an Enterobacteriaceae which is selected from the Pseudomonadales and Enterobacteriaceae species which is selected from the group consisting of organisms such as Pseudomonas, Acinetobacter, Stenotrophomonas, Burkholderia, Serratia, Proteus, Klebsiella, Enterobacter, Citrobacter, Salmonella, Shigella, Providencia, Morganella, Cedecea, Yersina and Edwardsiella species and Escherichia coli. 
Spoj u skladu s patentnim zahtjevima 1 do 8 ili njegova farmaceutski prihvatljiva sol, za uporabu u liječenju gram–negativne bakterijske infekcije, pri čemu je bakterijska infekcija odabrana iz vrsta Pseudomonadales i Enterobacteriaceae koje su odabrane iz skupine koja se sastoji od vrsta Pseudomonas, Acinetobacter, Stenotrophomonas, Burkholderia, Serratia, Proteus, Klebsiella, Enterobacter, Citrobacter, Salmonella, Shigella, Providencia, Morganella, Cedecea, Yersina i Edwardsiella i Escherichia coli.
The composition according to claim 1, characterized in that, in step d), the formulation is prepared by fluidized-bed spray granulation method, comprising following steps: taking a part of filling agent, dissolving it with purified water, adding flavoring agent to dissolve by well-stirring to give slurry; adding well-prepared three Extracts into aforesaid slurry stepwise, stirring, adjusting density of the slurry, online filtering; putting the rest of filling agent into a granulator; performing spray granulation by adjusting granulating parameters; drying; granulating with a sieve; mixing totally and packaging to obtain the final product. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time, da se u koraku d) pripravak pripravlja postupkom granulacije raspršivanjem u fluidiziranom sloju, koji obuhvaća slijedeće korake: uzimanje dijela punila, otapanje s pročišćenom vodom, dodavanje sredstva za poboljšanje okusa koje se otapa snažno miješanje da se dobije gusta otopina; dodavanje dobro pripremljena tri ekstrakta u prethodno navedenu suspenziju korak po korak, miješanje, podešavanje gustoće suspenzije, online filtriranje; stavljanje ostatka punila u granulator; izvođenje granulacije raspršivanjem podešavanjem granulacijskih parametara; sušenje; granuliranje sitom; potpuno miješanje 1 pakiranje kako bi se dobio konačni proizvod.
The pharmaceutical composition for use according to claim 1, wherein the ocular lubrication deficiency is an undesirable ocular boundary lubrication resulting from aqueous or evaporative dry eye disease, Sjögren's syndrome, keratoconjunctivitis sicca, androgen deficiency, meibomian gland disease, estrogen replacement therapy, contact lens wear, refractive surgery, reduced tear film breakup time, allergy, ocular surface disorders, increased protease levels in the tear film and at the ocular surface, chronic inflammation, hyperosmolarity or aging. 
Farmaceutska kompozicija za primjenu prema patentnom zahtjevu 1, pri čemu nedostatak okularne lubrikacije je neželjena okularna granična lubrikacija koja nastaje od bolesti suhog oka uslijed nedostatka vodenog filma ili isparavanja, Sjögren-ovog sindroma, keratoconjunctivitis sicca, nedostatka androgena, bolesti meibomian žlijezda, zamjenske terapije estrogena, nošenja kontaktnih leća, refraktivne operacije, smanjenog vremena prekida suznog filma, alergije, poremećaja okularne površine, povećanih nivoa proteaze u suznom filmu i na okularnoj površini, kronične inflamacije, hiperosmolarnosti ili starenja.
or a pharmacologically acceptable salt thereof. 
NA ci ili njegove farmakološki prihvatljive kiselinske adicijske soli.
an effective amount of a platinum-based agent, for use in a method of treating recurrent ovarian, peritoneal, or fallopian tube cancer in an individual, wherein the individual has received a prior chemotherapy and has a treatment free interval for more than about three months prior to initiation of the treatment. 
(b) djelotvornu količinu sredstva na bazi platine, namijenjenu upotrebi u postupku liječenja recidiva raka jajnika, peritoneuma ili jajovoda kod osobe, gdje je osoba prethodno primila kemoterapiju i ima interval bez liječenja dulji od otprilike tri mjeseca prije početka liječenja.
In an exemplary embodiment, the monomers comprise Formula (Vb): 
Spoj sukladno zahtjevu 1, naznačeno time, da spoj ima Formulu (IIc):
In order to evacuate the at least two thermoblocks connected with the brewing chambers, valve means can be provided to selectively vent air through the hot water outlet and into the thermoblocks for emptying the thermoblocks. 
Kako bi se ispraznilo najmanje dva termobloka povezana s komorama za kuhanje, može se ugraditi ventile za selektivno upuhivanje zraka kroz izlaz za vruću vodu, te u termoblokove, radi pražnjenja termoblokova.
Use of claim 19, wherein the HMGB1-associated pathologies are stenosis, restenosis, atherosclerosis, rheumatoid arthritis, autoimmune diseases, tumors, infective diseases, sepsis, acute inflammatory lung injury, lupus erythematosus, neurodegenerative diseases, diseases of the central and peripheral nervous system and multiple sclerosis. 
Uporaba prema patentnom zahtjevu 20, naznačena time što su patologije povezane sa HMGB1 stenoza, restenoza, ateroskleroza, reumatoidni artritis, autoimune bolesti, tumori, infektivne bolesti, sepsa, akutna inflamatorna povreda pluća, lupus eritematodes, neurodegenerativne bolesti, bolesti središnjeg 1 perifernog živčanog sustava i multipla skleroza.
The use according to anyone of the preceding claims, wherein the white blood cells are primary cells, immortalized cells and/or transgenic cells. 
Uporaba prema zahtjevu 13 naznačena time da je za transport teretne molekule u bijele krvne stanice i/ili neuronske stanice, naročito kod pacijenta koji se treba liječiti.
is selected from the group consisting of -O-, -S- and -SO-; 
se L2 odabire iz skupine koju sačinjavaju -O-, -S-, i -SO-;
The method of claim 26, wherein said cooling comprises cooling the composition from heated to below the glass transition temperature to about room temperature. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 26, gdje se navedeno hlađenje sastoji u hlađenju pripravka s temperature ispod staklišta na sobnu temperaturu.
Use of the kit of any of clauses 1-7 in a method of preparing a subject's bowel for a medical procedure. 
Komplet iz bilo kojeg od patentnih zahtjeva 1-11, pri tome neke ili sve namirnice još sadrže vitamin C ugrađen u njih.
In both arms, the level of formula (II) in solution was monitored over time, by withdrawing a small sample of the fluid and comparing its LC-MS response to that of a matrix-matched external standard (i.e. 
U oba kraka, razina formule (II) u otopini se prati tijekom vremena, povlačenjem malog uzorka tekućine i uspoređivanjem njenog LC-MS odgovora s onim matriksnog vanjskog standarda (tj.
The composition of claim 3 wherein the cognate acid of the acid salt is malic acid, citric acid, tartaric acid, oxalic acid, succinic acid, adipic acid, fumaric acid, acetic acid, formic acid, lactic acid, maleic acid, phthalic acids, creatinine hydrochloride, pyridoxine hydrochloride, thiamine hydrochloride, cysteine hydrochloride, glycine hydrochloride, cystine dihydrochloride, peptides, toluene sulfonic acid, methanesulfonic acid, ethanesulfonic acid, phosphoric acid, phosphonic acid, orthophosphoric acid, hydrochloric acid, sulfonic acid, sulfuric acid, nitric acid, sodium metabisulfite, potassium phosphate monobasic, polyphosphoric acid, polyvinylsulfuric acid, polyvinylsulfonic acid, or a mixture of any two or more thereof. 
Sastav prema patentnom zahtjevu 3, naznačen time, da odgovarajuća kiselina kiselinske soli jest jabučna kiselina, citronska kiselina, vinska kiselina, oksalna kiselina, jantarna kiselina, adipinska kiselina, fumarna kiselina, octena kiselina, mravlja kiselina, mliječna kiselina, malcinska kiselina, ftalnc kisclinc, krcatinin-hidroklorid, piridoksin- hidroklorid, tiamin-hidroklorid, cistein-hidroklorid, glicin-hidroklorid, cistin-dihidroklorid, peptidi, toluensulfonska kiselina, metansulfonska kiselina, etansulfonska kiselina, fosforna kiselina, fosfonijeva kiselina, ortofosforna kiselina, solna kiselina, sulfonska kiselina, sumporna kiselina, dušična kiselina, natrijev metabisulfit, monobazični kalijev fosfat, polifosforna kiselina, polivinilsumporna kiselina, polivinilsulfonska kiselina ili smjesa od bilo koje dvije od tih kiselina ili od više njih.
The process according to claim 1, wherein following pH modification, the silicate-containing product is separated from the liquid phase and dried, thereafter comprising less than 50% by weight of said hydrophobically modified polyalkyleneimine relative to the amount of hydrophobically modified polyalkyleneimine prior to pH modification. The process according to claim 1, wherein following pH modification, the silicate-containing product is separated from the liquid phase and dried, thereafter comprising less than 66% by weight of said hydrophobically modified polyalkyleneimine relative to the amount of hydrophobically modified polyalkyleneimine prior to pH modification. The process according to claim 40, wherein a hydrophobically modified polyalkyleneimine recovered in step g) is implemented as the hydrophobically modified polyalkyleneimine of step b). 
Proces prema bilo kojem od zahtjeva 21 do 24, naznačen time što nakon modifikacije pH, proizvod koji sadrži silikat se odvaja od tekuće faze 1 suši, nakon čega sadrži manje od 30%, poželjno manje od 50%, i najpoželjnije manje od 66% težine tog hidrofobno modificiranog polialkilenimina u odnosu na količinu hidrofobno modificiranog polialkilenimina prije modifikacije pH. Proces prema zahtjevu 23, naznačen time što se hidrofobno modificirani polialkilenimin dobiven u koraku g) implementira kao hidrofobno modificirani polialkilenimin iz koraka b), taj dobiveni hidrofobno modificirani polialkilenimin poželjno se implementira u količini koja predstavlja barem 30%, poželjno barem 50%, i najpoželjnije barem 66% tog hidrofobno modificiranog polialkilenimina iz koraka b).
In still other embodiments, the method includes dissolving the free base in ethanol at a temperature above about 30° C., protonating the dissolved free base with hydrochloric acid (e.g., in an aqueous solution, such as a 30-40 wt % aqueous solution, e.g., a 36.5 wt aqueous solution) at a temperature below about 30° C., and allowing crystalline form I to form at a temperature below about 30° C. 
Postupak proizvodnje kristalnog oblika I spoja predstavljenog slijedećom strukturnom formulom: gdje je kristalni oblik I naznačen sa barem tri pika difrakcije x-zraka na prahu pri 20 kutovima odabranim od 12.5, 12.9", 14.8%, 20.0, 22.2" 1 26.1% ili 12.5%, 14.8%, 22.2% 126.1"; koji postupak sadrži: otapanje slobodne baze spoja u etanolu pri temperaturi ispod 30*C; protoniranje otopljene slobodne baze sa klorovodičnom kiselinom; te HR P20150327 T1 dopuštanje da se stvori kristalni oblik I hlađenjem otopljene protonirane slobodne baze (npr., pri temperaturi ispod 30*C).
The polypeptide of claim 7, wherein the clotting factor is selected from the group consisting of FVII, FVIIa, FIX, FIXa, FX, and FXa. 
Polipeptid prema patentnom zahtjevu 3 ili 7, naznačen time što je faktor zgrušavanja odabran iz skupine koja se sastoji od FVII, FVIIa, FIX, FIXa, FX, i FXa.
Mice that express antibodies that comprise a light chain having a human Vλ domain fused to a Ck and/or Cλ region are described. 
Metoda za dobivanje sekvence nukleinske kiseline koja šifrira varijabilnu domenu teškog i/ili lakog lanca koja se sastoji od: